BJH - volume 8, issue 4, august 2017
T. Feys MBA, MSc
As usual, June was a very busy month for lymphoma specialists, with back to back, international meetings. This report will summarize some key data related to non-hodgkin lymphoma, presented during the 2017 International Conference on Malignant Lymphoma (ICML; Lugano June 14–17) and the 2017 annual meeting of the European Hematology Association (EHA; Madrid June 22–25). We would like to acknowledge Prof Ann Janssens (University Hospital Leuven) for her help in selecting the abstracts presented here.
(BELG J HEMATOL 2017;8(4):158–64)
Read moreBJH - volume 8, issue 4, august 2017
T. Feys MBA, MSc
(BELG J HEMATOL 2017;8(4):166–7)
Read moreBJH - volume 8, issue 3, june 2017
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2017;8(3):125–6)
Read moreBJH - volume 8, issue 2, march 2017
T. Feys MBA, MSc
(BELG J HEMATOL 2017;8(2):87–8)
Read moreBJH - volume 8, issue 2, march 2017
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2017;8(2):89)
Read moreBJH - volume 7, issue 5, october 2016
T. Feys MBA, MSc
From June 3rd till June 6th, Chicago again formed the background for the biggest cancer congress in the world. Notwithstanding the fact that solid tumours remain the main focus of the annual meeting of the American Society of Clinical Oncology (ASCO), the meeting program also included some interesting lectures on haematological malignancies. The aim of this report is not to discuss all these studies, but will address some of the key presentations on haematological cancer from ASCO 2016. For a more complete overview we would like to refer to the congress website, where all abstracts and a plethora of webcasts can be found.
(BELG J HEMATOL 2016;7(5):203–6)
Read moreBJH - volume 7, issue 4, september 2016
T. Feys MBA, MSc
Defects in the platelet haemostasis can lead to the development of thrombocytopaenia and thrombosis. During the 2016 annual meeting of the European Hematology Association (EHA) several presentations focussed on prognostic, clinical and biochemical aspects of these conditions. In addition to this, several new therapeutic options were discussed together with a study looking into cancer-associated thrombosis.
(BELG J HEMATOL 2016;7(4):170–3)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
